PCFA's vision is to reduce the impact of prostate cancer on Australian men, their partners, families and the wider community.

Through our research program, we fund innovative research projects aimed at accelerating improved clinical tests and treatments that contribute to the goals of eliminating death from prostate cancer and enhancing the physical and mental well-being of men living with the disease.

Outcome of the 2025 Funding round

PCFA is delighted to announce that the 2025 Priority Impact Research Award – Ignite Synergy Grant valued at $5 million (inclusive of GST) has been awarded to the Peter MacCallum Cancer Centre for their Breakthrough Theranostics research project.

This is PCFA’s largest single research investment to date, supporting a national program with the potential to fundamentally change prostate cancer care.

The project entitled Breakthrough Theranostics: New Targets, Isotopes, and AI-Enhanced Predictive Biomarkers to Drive Patient-Centred Impact will be led by Professor Michael Hofman from the Peter MacCallum Cancer Centre. It is a three-year, multi-institutional program that brings together leading experts from around Australia to advance next-generation theranostics – identifying new molecular targets and designing novel radioactive isotopes to deliver more precise, effective, and patient-centred treatments.

More details can be found here